Harrow, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. on October 2, 2019. The report addresses the resolution of a federal lawsuit involving the Company and Allergan USA, Inc. ("Allergan"), originally filed in the U.S. District Court for the Central District of California.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a legal event. No economic consideration was exchanged between the parties related to the resolution of the dispute.
Material Changes
The primary material event is the voluntary dismissal of pending appeals by both Harrow and Allergan via a joint stipulation filed on October 2, 2019. This action formally resolved all pending disputes arising from the lawsuit, which had previously resulted in a federal jury trial outcome disclosed in May 2019. The resolution eliminates potential future legal fee expenditures connected to this specific matter.
Outlook, Risks, and Management Commentary
Management states that the Company does not expect the outcome of this litigation to materially change the business plans or future prospects of its wholly-owned subsidiary, ImprimisRx. The filing indicates that the legal contingency regarding this specific lawsuit has been removed.
Key Facts for Investor Verification
- The lawsuit with Allergan USA, Inc. has been fully resolved with no financial settlement exchanged.
- All pending appeals related to the lawsuit have been voluntarily dismissed by both parties.
- Management asserts no material impact on the business plans of the ImprimisRx subsidiary.
- Future legal fees associated with this specific litigation are no longer anticipated.